Ongoing research aims to expand the applications of azacitidine to other hematologic and solid tumors. Studies are exploring its use in combination with other chemotherapeutic agents, targeted therapies, and immunotherapies to enhance its efficacy. Researchers are also investigating biomarkers to predict response to azacitidine, which could lead to more personalized treatment strategies. Clinical trials are continually evaluating new dosing regimens and administration methods to optimize patient outcomes.
